Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus TENOFOVIR ALAFENAMIDE FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus TENOFOVIR ALAFENAMIDE FUMARATE.
EMTRIVA vs TENOFOVIR ALAFENAMIDE FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Tenofovir alafenamide fumarate is a nucleotide reverse transcriptase inhibitor. It is a prodrug that is hydrolyzed intracellularly to tenofovir diphosphate, which inhibits HIV reverse transcriptase and hepatitis B virus polymerase by competing with the natural substrate deoxyadenosine 5'-triphosphate and by DNA chain termination after incorporation into viral DNA.
Emtricitabine 200 mg orally once daily.
25 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Terminal elimination half-life is approximately 0.51 hours (range 0.37-0.77 hours) for tenofovir alafenamide, while the active metabolite tenofovir diphosphate has a prolonged intracellular half-life of approximately 150-180 hours in PBMCs, supporting once-daily dosing.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Following oral administration, approximately 32% of the tenofovir alafenamide dose is excreted unchanged in urine via active tubular secretion and glomerular filtration; the remainder is eliminated as metabolites, primarily through fecal excretion (approximately 47%) and minor biliary elimination, with less than 1% excreted unchanged in feces.
Category C
Category A/B
Antiretroviral, NRTI
NRTI